Monday, June 24

Experimental drug shields pancreas from kind 1 diabetes assault



Experimental drug shields pancreas from type 1 diabetes attack
Cell-surface mAb43 binding reduces antigenic exposure of membrane-bound insulin. Credit: Diabetes (2024). DOI: 10.2337/db23-0568

Scientists at Johns Hopkins Medicine say that an experimental monoclonal antibody drug called mAb43 appears to prevent and reverse the onset of clinical type 1 diabetes in mice, and in some cases, to lengthen the animals’ lifespan.

The drug is unique, according to the researchers, because it targets insulin-making beta cells in the pancreas directly and is designed to shield those cells from attacks by the body’s own immune system cells. The drug’s specificity for…


Leave a reply